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Iohexol is a commonly used second generation non-ionic iodinated contrast agent with a multitude of advantages such 
as low osmolarity and competent intravenous countenance having minimum adverse reactions. Our study anticipated to 
improve the efficacy of Iohexol as a contrast enhancing agent for Computed Tomography, by envisaging bio-compatible 
albumin based Iohexol nanoparticles. This nanoparticulate system was developed primarily to enhance the anatomic 
imaging while increasing its residence time in the blood pool. Towards this goal, we developed Iohexol albumin nanopar-
ticles using glutaraldehyde as a cross linking agent, and Polyethylene glyocol Iohexol albumin nanoparticles by physical 
adsorption to ameliorate its circulation time. These formulations were studied in comparison to the clinically available 
Iopamidol™. Both Iohexol albumin nanoparticles and Polyethylene glyocol Iohexol albumin nanoparticles were charac-
terized for its size, physicochemical properties and entrapment efficiency. Iohexol albumin nanoparticles showed a size 
range of 254 ± 5 nm and post surface modification the size of Polyethylene glyocol Iohexol albumin nanoparticles was 
found to be 283 ±7 nm in diameter, with and entrapment efficiency Iohexol as of 85%. Further, In vivo computed tomog-
raphy imaging in New Zealand white rabbits for the developed formulations manifested an enhancement in the anatomical 
structures of heart, liver and kidneys along with an increased residence time in the blood pool of 3 h in contrast to 
Iopamidol™. Our study interprets that Polyethylene glyocol Iohexol albumin nanoparticles have prolonged residence 
time producing much greater conspicuity of anatomic features and warrants further detailed study of the formulation in 
disease models.
KEYWORDS: Nanoparticle, Contrast Agent, Computed Tomography, Iohexol, Albumin, Rabbit.
INTRODUCTION
Computed tomography (CT) is one of the extensively used
imaging modalities for pre-clinical and clinical investiga-
tions of a wide array of medical conditions. X-rays, which
are a source of ionizing radiation made use in CT enables
the visualization and distinction of tissues inside organs.
Further, this imaging technique is proficient in acquiring
three dimensional images of soft tissues including blood
vessels and brain. Contrast agents are imperative in radio-
imaging and radio-therapeutics. Remarkable furtherance in
augmenting the composition of these contrast agents have
made them invulnerable. A study reviewed that, iodinated
contrast agents which are clinically approved and hav-
ing low osmolarity are assimilated rapidly by soft tissues,
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bones and blood vessels enabling the visualization of the
anatomical structures with utmost coherence.12 Nonethe-
less, the risk kindred with conventional contrast agents
have not been nullified. However, due to the snag of
rapid renal clearance of conventional iodinated contrast
agents, discrepancy in the levels of contrast would vary
during the course of the study. In addition, X-ray atten-
uation of iodine is not efficacious for clinical CT that
uses high-energy X-rays. Further, rapid renal clearance, is
associated with significant adverse consequences such as
anaphylactic reactions causing urticaria, laryngeal edema,
bronchospasm and non-anaphylactic reactions including
pulmonary edema, cardiac arrhythmias, nausea, seizures
and renal failure which are sometimes fatal in nature.3 This
has generated interest in engineering novel nano sized con-
trast agent formulations to subdue the shortcomings of the
conventional contrast agents, simultaneously ameliorating
the radiograph.
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Enormous amount of formulations are augmented as a
substitute for CT contrast like gadolinium chelates and
clusters of tungsten.45 Integration of nano-composite con-
trast formulations into clinical mainstreams will revolu-
tionize the radio-diagnostic techniques. Nano-medicine has
metamorphosed the area of diagnosis and therapy. The
therapeutic applications of nano-formulations include tar-
geted drug delivery, various imaging modalities such as
PET, MRI, fluorescent and photoacoustics, gene delivery,
thermal ablation and many more.6–8 However, implemen-
tation of nanotechnology in radio diagnostic techniques to
develop contrast agent for CT is now being developed.9
A variety of materials are used to develop nanocompos-
ite contrast agents such as bromine, platinum, bismuth,
iodine.10–13 Such core are usually modified using lipids,
proteins, polymers, in order to enhance its solubility, bio-
compatibility and its residence time in blood pool.14 The
reason to select nanoparticle for contrast agent study is
because clinically approved CT contrast agents are small
molecules and are therefore swiftly excreted via the kid-
neys. Nanoparticles, on the other hand, can be synthesized
to be larger than the renal fenestrae and therefore remain
in the bloodstream. They can carry a high load of con-
trast agent compared with small molecules besides coating
material properties also dominates blood circulation time.
The long circulating contrast agents have ability to visual-
ize the blood vessels for longer duration in case of image-
guided surgeries. Biocompatible albumin nanoparticles has
an added advantage for individuals having contraindica-
tion for conventional iodinated agents due to renal insuf-
ficiency and allergic reactions.15 The formulation in the
present study is biocompatible and cost effective having
potential for further clinical application.
Liposomal CT contrast moieties have been widely stud-
ied for pre-clinical applications using water-soluble iod-
inated contrast agents.1617 A study showed that, lipid
based agents were rapidly cleared by the reticuloendothe-
lial system (RES), and thus were used mainly to detect
solid tumors of the liver or spleen. However, these are
usually surface modified with Polyethylene Glycol (PEG)
to increase their circulation time.18 In contrast, liposome
nano-composites of contrast agents for CT have some lim-
itations, including low encapsulation efficiency, fast burst
release of drugs and poor storage stability.19 Nano formu-
lated contrast enhancing agents have the ability to with
stand physiological stress along with improved biological
stability; prolong half-life (t1/2 in the blood pool and long-
term storage. All these advantages make them appealing as
theragnostic agents over conventional ones.20–22 Nanopar-
ticulate contrast system would be useful to reduce dose of
intravenous administration, along with appreciable sensi-
tivity and specificity of imaging modalities. This has led to
the development of several iodine based nanoformulations
for higher t1/2 and in lesion signal enhancement without
multiple administrations of contrast.23–25
Protein based nanoparticle drug delivery system are 
studied to have diminished toxicity, and are non-antigenic 
in vivo. Furthermore, albumin nanoparticles are non-
immunogenic, biocompatible and biodegradable, which is 
easy to purify and water soluble allowing easy intravenous 
administration.26 Albumin nanoparticles are cleared via 
hepatobiliary or renal route, hence complete clearance is 
achievable in few hours post administration. Besides it can 
be safely used in subjects with compromised renal or hep-
atic function. Albumin can been modified to create novel 
nanostructures for drug delivery applications. Modification 
with Polyethylene Glycol (PEG) reduces opsonization by 
reticulo endothelial system, while prolonging its circula-
tion in the blood pool.27–29 Iohexol is a commonly used 
time tested second-generation contrast agent, which has 
a proficient residence time for visualization of anatomic 
structures.
This study was aimed to develop and evaluate albu-
min nanocarrier system of iohexol to provide high con-
trast agent loading for computed tomography imaging, to 
prolong circulation of contrast agent in the blood and to 
improve organ vascularization with minimal side effects. 
We developed Iohexol Albumin Nanoparticles (IAP) and 
also surfaced modified it by PEGylation (P-IAP) and eval-
uated in pre-clinical setup.
MATERIALS AND METHOD
Formulation of Albumin Based
Iohexol Nanoparticles
Iohexol nanoparticles were prepared by coacervation tech-
nique, followed by cross linking with glutaraldehyde. 
Iohexol (Histodenz, Sigma Aldrich@, Biotechnology LP 
and Sigma-Aldrich Co., USA) at a concentration of 350 mg 
of iodine per milliliter was solubilized using 2%v/v of 
albumin solution. IAP were prepared by method as 
described earlier.30  Briefly, Iohexol was incubated in 
Human Serum Albumin (HSA) solution (Life-line pharma 
Pvt Ltd., Colombo, Shri Lanka) for 10 min, and the pH was 
adjusted to alkaline side using 1% NaOH (Merk, India). 
Ethanol (Sterling chemicals and Alcohols Pvt. Ltd. Pune, 
India) was added as a desolvating agent at the rate of 1 mL/
min under continuous stirring for 10 min. Further, 
glutaraldehyde (SD Fine chemicals Pvt. Ltd., Mumbai, 
India) was added slowly to induce particle cross linking 
and allowed to stir for 3.5 h. Twelve batches from PN1 to 
PN12 (four of each glutaraldehyde concentration) were 
studied for the effect of glutaraldehyde concen-tration at 
20, 25, 30 L/mL and stirring time at 1, 2, 3 and 3.5 h on 
particle size and polydispersity index (PI) using 32 factorial 
design and response surface methodology.
PEGylation, Lyophilization and
Sterilization of IAP
Optimized albumin nanoparticle batch PN8 with particle 
size 254 nm and P.I. of 0.20 was subjected to surface
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nanoparticle formulation was determined by absorption of
UV light at 254 nm wavelength with a Jasco UV 630 Spec-
trophotometer system at predetermined time intervals of 0,
30, 60, 90 days.
Determination of Entrapment Efficiency
Entrapment efficiency of Iohexol in IAP and P-IAP was
determined by RP-HPLC (Jasco PU 2089 pump, Jasco
UV 2070 plus detector). A standard curve with known
concentration of Iohexol was developed so as to quan-
tify the amount of iohexol in the developed formula-
tion. Extinction coefficient of Iohexol was calculated as
26,600 M−1cm−1. A range of Iohexol working solu-
tion (2, 4, 6, 8 g/mL) was prepared from 1 mg/mL
stock solution. Iohexol was quantified at 254 nm, using
Technokroma C-18 column (25 cm× 4.5 mm, 0.5 m)
with acetonirile and water (99:01 v/v) at a flow rate of
0.5 mL/min. Further, entrapped iohexol in IAP and P-IAP
dispersion was extracted by ultracentrifugation at 9000
rpm for 10 min. The pellet obtained was digested with
0.5% trypsin solution. This was further centrifuged at 9000
rpm for 10 min and the supernatant obtained was filtered
(filter having a pore size of 0.22 ). This was diluted with
mobile phase and quantified by RP-HPLC. Percent entrap-
ment of iohexol in NPs was determined using formula:
Entrapment Efficiency = Total drug−Free drug
/Total drug×100
In Vitro Release of Iohexol
In vitro release of iohexol was studied by dialysis bag
method. Dialysis bag (MWCO 12–14 Kda, Sigma Aldrich)
containing 2 mL of IAP/P-IAP was placed in a conical
flask containing 200 mL of dissolution media (phosphate
buffered saline (PBS), pH—7.4). These flasks were kept
in shaker water bath maintained at 37 C under constant
agitation of 100 vibrations per min. 5 mL sample was
withdrawn at specific time intervals for a period of 4 h and
replaced with same volume of fresh medium. The released
contrast agent was quantified using a UV spectrophotome-
ter (Jasco UV630) at a wavelength of 254 nm. A graph of
% Iohexol release versus time was plotted. Contrast release
was studied using different release study models such as
Zero order, First order release and Higuchi model.
Animals
Animal experiments were performed with prior approval
from the Institutional Animal Ethics Committee (IAEC/04-
2010). All the animal studies were carried out under
the guidelines complied by CPCSEA (Committee for
the Purpose of Control and Supervision of Experi-
ments on Animals). New Zealand white rabbits were
housed and maintained according to ARRP guidelines
(http://www.animalethics.org.au/_data/assets/pdf_file/0013/
222511/housing-rabbits-scientific-institutions.pdf). Food and
modification with PEG 1500, PEG 4000 and PEG 6000 
by physical adsorption, at 3 concentration levels i.e., 0.4, 
0,8 and 1.2% w/v by incubation for 3 h. PEG 4000 was 
chosen for further study and added to the previously opti-
mized IAP and its effect on PI and particle size was further 
studied. Lyophilization of both IAP and P-IAP was carried 
out using Martin Christ Epsilon 2, 4 LSC freeze dryer. 
Various cryoprotectants like sucrose, mannitol, trehalose 
were screened at different concentrations. But 20% 
Mannitol was selected as a suitable cryoprotectant after 
screening for different physical parameters. The system was 
evacuated using 0.05 m · bar vacuum and freezing was done 
at −50 C for 5 h followed  by primary drying at −50 
C to −20 C for 20 h and sec-ondary drying at 10 
C to 30 C for 14 h. Lyophilized NPs were collected and 
characterized further. Lyophilized formulations (Ly IAP and 
Ly P-IAP) filled in amber colour vials were packed in 
thermacol box along with coolent. Sterilization was 
performed by radiating the samples using 25 kGy of gamma 
radiation and sterilized formulations were prepared (S IAP, 
and S P-IAP). Doses were monitored with specific 
dosimeters during the entire process of sterilization. 
Optimized IAP, P-IAP, Ly IAP, Ly P-IAP, S IAP, and S P-
IAP batches were collected and characterized for further 
studies.
Characterization of Formulation
Preliminary characterization of IAP and P-IAP was carried 
out to screen parameters such as visual appearance, pH, 
particle size and polydispersity index (PDI), transmission 
electron microscopy (TEM), Confocal microscopy. PDI 
was determined using N5 Beckmann sub-micron particle 
size analyzer. These particles were further characterized 
by transmission electron microscopy (TEM) to determine 
the size and coating around IAP. The samples for TEM 
were prepared by sonicating the samples in Milli Q at 
a concentration of (10 g/mL). coated copper grids and 
allowed to settle for 3 to 5 min then these grids were 
further dried under UV lamp and stained with 1% uranyl 
acetate solution. Dried sample were analyzed using trans-
mission electron microscope (Philips CM, operating volt-
age 20 to 200 Kv model with resolution 2.4 Å) and area 
of interest was scanned at higher magnification (80,000×–
200,000×) to confirm the surface modification and shape 
of NPs. Confocal microscopy of the selected nanoparticle 
was done using confocal microscope Bio Rad MRC 1024 
with 2 microscopes as Nikon E60 and dual line Argon 
ion laws to confirm the surface modification and shape of 
nanoparticles.
Stability Assessment of IAP and P-IAP
It was studied at various conditions viz. refrigeration 
25 ± 2C/60 ± 5%RH, 30 ± 2C/65 ± 5%RH, 40 ± 2C/75 ± 
5%RH where the formulations were analyzed for appear-
ance, pH, particle size, polydispersity index, syringeabil-
ity and injectability. The iodine concentration of albumin
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water to the animals were supplied ad libitum. Animals
were fasted for 3 h before injecting the contrast. Dosing
of the animals was done as follows:
Group 1: Animals were injected with 3.170 mL/kg · b.wt
of IAP
Group 2: Animals were injected with 3.170 mL/kg · b.wt
of P-IAP
Group 3: Animals were injected with 1 mL/kg · b.wt of
Iopamidol™ (370 mg/mL).
Prior to intravenous administration of the contrast,
all the animals included in the study were anesthetized
with an intramuscular (IM) injection of ketamine and
xyalazine mixture (35 mg/kg ·b.wt. ketamine and 5 mg/kg ·
b.wt. xylazine) during each imaging session. Rabbits were
placed on patient bed in prone position. Iohexol nanopar-
ticulate formulations (Dose for rabbit = Absolute human
dose ×0.07) and standard contrast agent Iopamidol™
(1 mL/kg body weight) was administered as a slow bolus
via marginal ear vein.31
Whole body CT scan images were acquired through-
out the course of study using four slice multi-detector row
CT scanner (Sensation 4 CT, Siemens, Germany) operated
at 80 kV and 165 mA/s, with a reconstruction interval
of 3 mm. A pre and post contrast scan images of rabbit
were acquired. Scan was performed at different time points
such as 0, 5, 15, 30, 60 and 180 min following injection
of contrast formulation. Projection images were used to
reconstruct tomograms with Syngo software (Siemens AG,
Germany) using Kernal B 30 s medium smooth and FOV
of 214 mm keeping slice width of 3 mm having 2.5 mm
collimation. Contrast formulations were studied in each
rabbit with flush out period of 2 weeks between injec-
tions of each formulation. Mean attenuation (in Hounsfield
unit) was determined using Imalytics 3.0 (Philips Corpo-
rate Technologies, Germany) translational imaging soft-
ware in axial plane at different region of interest like aorta,
heart, kidney (medulla and cortex) and liver to note the
clearance of contrast agent at each time point in each of
the above region. The mean difference in attenuation post
injection and pre-injection of the contrast agent defined
as relative enhancement, was measured and results were
plotted as time–attenuation curves.
RESULTS
Solubility Study
1000 mg of contrast agent was solubilized in 1 mL of
1% HSA solution with proper viscosity which is an adept
criteria for any contrast agent. Hence 1% HSA solution
was found to be a good carrier for Iohexol nanoparticles
with good entrapment efficiency.
Optimization of Albumin Nanoparticles
Effect of glutaraldehyde concentration at three levels such
as 20, 25, 30 l/mL was studied using 32 factorial design.
Batches with glutaraldehyde concentration of 20, 25 and
Figure 1. Effect of glutaraldehyde concentration and stirring
time on particle size of different iohexol nanoparticle batches.
30 l/mL at the end of 3.5 h resulted in particle size of
238 nm, 254 nm, 450 nm and P.I. of 0.30, 0.20, 0.16
respectively. From above results it could be concluded that
glutaraldehyde concentration of 25 l/mL was well within
the acceptable range of stability, dispensability and suffi-
cient to produce rigid nanoparticles with narrow particle
size distribution (Figs. 1 and 2).
The effect of stirring time on particle size and P.I.
was optimized using response surface method. Stirring for
3.5 h resulted in nanoparticles which were stable, hard and
formed pellets after centrifugation which was indication of
nanoparticle formation (Fig. 3).
PEGylation of Albumin Nanoparticles
PEG 4000 at concentration of 0.8% showed increase in
particle size from 254 to 283 nm and lowered the P.I. from
0.20 to 0.14 indicating the surface modification or surface
coating. Effect of different PEGs and their concentration
on PI and particle size is shown in Figure 4.
Figure 2. Effect of glutaraldehyde concentration and stirring
time on polydispersity index of different iohexol nanoparticle
batches.
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Figure 3. Effect of stirring time on iohexol nanoparticle batch
PN 8 on particle size and polydispersity index.
Characterization and Entrapment Efficiency of
IAP and P-IAP
Synthesized IAP and P-IAP appeared to be pale yellow in
colour and odourless with no signs of instability till 24 h.
The mean particle size of IAP and P-IAP was found to
be 254± 5 nm and 283± 7 nm respectively, with a nar-
row particle size distribution. P.I. takes into account the
refractive index of the solvent angle of measurement and
also variance of distribution. The P.I. of IAP was found to
be 0.20 and in case of P-IAP, the P.I. was lowered from
0.20 to 0.14. This shift in P.I. indicates surface modifica-
tion. PH was maintained at 6.5 to 7.5. Further, both IAP
and P-IAP showed 92% (w/v) per cent content of iohexol,
85% entrapment efficiency with excellent syringebility
and injectablity. TEM and confocal microscopy images of
IAP and P-IAP confirmed the spherical shape and nar-
row size distribution of the particles. (Figs. 5(a, b) and
6(a, b)) In IAP and P-IAP, particles were in range of
125 nm to 290 nm and 189 nm to 300 nm respectively and
Figure 4. Effect of concentration of PEGs on particle size and
polydispersity index of IAP.
there was no significant difference in appearance of both
formulation.
Characterization of Lyophilized and Sterilized
Nanoparticle Formulations
Both Lyophilized nanoparticles were found to be easily
redispersible in distilled water. The mean particle size of
Ly IAP and Ly P-IAP was found to be 321± 5 nm and
327± 7 nm respectively which shows that there was a
drastic increase in particle size after lyophilization. P.I
of lyophilized IAP and P-IAP was found to be 0.09 and
0.36 respectively, indicating a monomodal distribution of
dispersed system after lyophilization. However, P.I. lower
than 0.1 might be associated with a high homogeneity
in particle population. Confocal microscopy images of Ly
IAP and Ly P-IAP confirmed the spherical shape and nar-
row size distribution of the particles. (Figs. 6(c, d)). There
was no significant change was observed in other parame-
ters. Also there was no significant difference found in all
the parameters after sterilization.
In Vitro Release of Iohexol
Both IAP and P-IAP showed first order release followed by
Higuchi release pattern (R2 = 0.9860 and 0.9443 respec-
tively, indicating matrix dependent release) (Fig. 7). IAP
showed >30% release at the end of 1 h and >95% release
at the end of 4 h. However, P-IAP showed >50% release
at the end of 1 h and entire release of contrast till 4 h.
(Fig. 8) T50% of IAP and P-IAP was found to be 52 min
and 50 min respectively. According to the release pattern,
PEGylation (done by physical adsorption) of IAP did not
cause major variation in the release profile of the contrast
agent. There was no significant variation in release pattern
of after lyophilization or sterilization (Fig. 9).
Stability Results
Both the nanoparticles showed no change in colour and pH
was almost constant between 6.5 to 7.5. IAP were stable
at 25± 2 C/60± 5% RH but there was high increase in
particle size and decrease in iohexol content over the three
months of testing period. P-IAP formulation was stable at
25±2 C/60±5% RH as well as 30±2 C/60±5% RH
with good syringebility. There was slight increase in PI
up to 0.49 and decrease in iohexol content till the end of
three months. Effect of temperature on particle size and
polydispersity index of IAP and P-IAP at the end of three
months is shown by graph in Figure 10.
In Vivo Blood Pool Imaging
In vivo CT imaging of heart and aorta showed that IAP and
P-IAP provided significant visual contrast enhancement of
the intravascular space up to three hours (Fig. 11). In con-
trast, Iopamidol administration showed least contrast in
aorta up to 3 hours and most of the contrast was found in
the bladder after 1 h, which indicates early renal clearance.
J. Biomed. Nanotechnol. 15, 1–12, 2019 5
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Figure 5. TEM images of (a) IAP and (b) P-IAP.
Figure 6. Confocal microscopy images of (a) IAP (b) P-IAP (c) Ly IAP and (d) Ly P-IAP.
No abnormal physiological changes were observed during
imaging studies. Further, no extravasation of iohexol was
observed at the time of injection or post injection. P-IAP
also showed enhancement of kidney cortex up to 3 hours
Figure 7. Graph of cumulative Iohexol release versus square root of time between (a) IAP and Ly IAP; (b) P-IAP and Ly P-IAP.
after injection of contrast material and transient increased
attenuation in the medulla of kidney indicating early clear-
ance (Fig. 12). Average attenuation of P-IAP 3 h post
injection was 73.3, 96.1, 86.8 HU in heart, aorta and renal
6 J. Biomed. Nanotechnol. 15, 1–12, 2019
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Figure 8. Graph of % Iohexol release versus time of Ly IAP
and Ly P-IAP.
cortex respectively. Intensity of contrast in liver was found
to be relatively constant till 3 h. Prolonged enhancement
achieved in the blood pool after administration of IAP
and P-P-IAP demonstrates that albumin carriers are able
to circulate and reside in the blood while retaining the co-
encapsulated small molecular weight agents like iohexol
(Figs. 13, 14).
DISCUSSION
Assorted forms of contrast enhancing agents have been
used in radio diagnostic techniques, to ameliorate medical
Figure 9. Graph of % Iohexol release versus time between (a) Ly IAP and IAP (b) P-IAP and Ly P-IAP.
Figure 10. Graph showing effect temperature on (a) polydispersity index and (b) particle size of IAP and P-IAP.
imaging. Intravascular contrast agents are used in CT to
culminate the blood vessels and intensify the tissue struc-
tures of various organs such as brain, spine, kidney and
liver. However, in comparison to other pharmaceutical
compounds, these contrast media are not entirely devoid of
risk in systemic circulation. Limitations in the administra-
tion of contrast media could vary from minor physiolog-
ical disturbances to alarming systemic imbalance. Some
of the risk factors include allergy, asthma,3233 renal insuf-
ficiency and contrast induced nephrotoxicity.34 Contrast
induced nephropathy or post contrast acute kidney injury is
a condition which generally occur 48 h post-administration
of the contrast media,3536 where the impairment in renal
function results in an increased baseline level of creatinine
in serum.
Iohexol is one of the second generation contrast media
clinically used for CT, with high water solubility and low
osmolality have comparatively low risk of adverse effect.37
However, intravascular administration of such iodinated
contrast media leads to dilution in systemic circulation and
rapid renal elimination without any significant metabolism.
The half-life (t1/2 of such conventional contrast agent is
reported to be 30–60 min in subjects with normal renal
function.3 To combat the pitfalls of the conventional non-
ionic iodinated contrast agents, we engineered albumin
based iohexol nanoparticles, in view of decreasing renal
impairment as it bypasses renal clearance due to larger
size and cleared by hepatic route after opsonization by
J. Biomed. Nanotechnol. 15, 1–12, 2019 7
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Figure 11. Representative computed tomographic axial images of rabbit demonstrating contrast visualization and variation in
HU values of of heart and aorta acquired at various time points such as precontrast, 0, 5, 15, 30, 60 and 180 minutes after injection
of three different contrast agent formulations.
RES system and also increasing the half-life (t1/2 of the
contrast media in the blood pool.
Molecular imaging being an emerging area in the field
of radiology, diagnosing the molecular markers prior to
the onset of biological symptoms which appears earlier in
the clinical conditions plays a vital role in early and effi-
cacious treatment of the medical condition. CT is the most
Figure 12. Representative computed tomographic axial images of rabbit demonstrating contrast visualization and variation in
HU values of kidney cortex and medulla acquired at various time points such as precontrast, 0, 5, 15, 30, 60 and 180 minutes
after injection of three different contrast agent formulations.
convenient set up used for diagnosis clinically. Advance-
ment in the field of nanomedicine has focused on devel-
oping bio-compatible nanoparticles to be employed as
blood pool CT contrast agents, passive or active target-
ing agents.38 Owing to the growing community of renally
impaired patients and those sensitive to iodine, micelle
and liposome based contrast enhancing agents have been
8 J. Biomed. Nanotechnol. 15, 1–12, 2019
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Figure 13. CT enhancement in (a) heart (b) aorta and (c) liver after intravenous administration of Iopamidol, IAP and P-IAP.
acculturated as CT contrast media.14 Nanoparticles made
of natural and hydrophilic polymers, including proteins
such as gelatin, collagen, and albumin have been stud-
ied to be efficient drug carriers and are evaded by the
reticuloendothelial system.39 Albumin in particular has
been vastly explored among potential drug carrier system
which alleviates its stability not only during storage but
also in the systemic circulation. Albumin based nanopar-
ticles are studied to be non-toxic, non-antigenic and fea-
sible to scale up over other conventional drug delivery
systems.40–43 Based on these findings, our study formu-
lated protein based contrast media for CT. The synthesized
IAP showed excellent stability with a narrow size range
and efficient loading efficiency of Iohexol. The formulated
contrast media showed efficient solubility and sustained
release of Iohexol. These criteria marked the probable
increased in t1/2 in vivo. Our study is in concordance with
earlier reports where, albumin based nanoparticles loaded
Figure 14. CT enhancement in (a) kidney medulla and (b) kidney cortex after intravenous administration of Iopamidol, IAP and
P-IAP.
with anti-cancer drug with a size ranging between 100
and 150 nm were effective as targeted therapy for breast
cancers.44–46
The size of the nanoformulation prepared by desolva-
tion technique of synthesizing IAP is monitored by desol-
vating agent, pH and not the cross linker.4247 This study
was concordat with our results, showing an apt and stable
formulation at a concentration of 25 L/mL of glutaralde-
hyde, but variation with stability was affected by varying
stirring time.
Albumin is also well known for its efficacious drug
loading capacity due to the presence of various drug
binding sites like Suldow’s site.48–51 In agreement to the
aforementioned fact our study also determined potent
entrapment of iophexol. This hypothesis is supported by
a study by Zaho et al., where a hydrophobic drug pacli-
taxil was loaded into albumin forming nanocomposite,
with an entrapment efficiency of 95.3%.52 This mechanism
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of association of drug or contrast agent to the binding
site of albumin might be due to electrostatic adsorption of
charged molecules towards the content of charged amino
acids in the primary structure of albumin.4753
Due to define primary structure of albumin, it pro-
pounds diverse prospects for surface modifications due
to the amino and carboxyl groups.475455 Surface modi-
fication can be brought about by the formation of cova-
lent bond between the available functional groups and
desired ligands. On the contrary, surface modification
by electrostatic adsorption techniques are also utilized.
In such a combination of protein (albumin) and a lig-
and, albumin operates as a nanosystem carrier, while the
ligand plays a paramount role in augmenting the phar-
macokinetic parameters such as stability and increased
shelf life in blood pool.30 We adapted the electrostatic
surface adsorption technique to modify the surface of
IAP using PEG and thus producing the surface modi-
fied P-IAP. PEGylation of nanocomposite structures for
in vivo application is done to enhance the circulation time
of the nanocomposite which embeds drug or contrast agent
by fifty folds, while reducing their immunogenicity.56
In accordance to the hypothesis of PEGylation, our study
showed an efficient retention of the surface modified
P-IAP in circulation, showing enhanced anatomical struc-
tures in vivo. Further, studies showed a slow release of
5-fluorouracil and Rose Bengal from PEGylated albumin
nanoparticles.5758
Synthesized IAP and P-IAP were studied to be highly
stable in aqueous suspension with least clogging and
excellent syringebility. Studies show that Human serum
albumin based nanoparticles are stable in suspension
at 4 C for a period of 6 months, and lyophilization
extended their shelf life, where 5% glucose was used as a
stabilizer.59–61 In contrast to this study, our study showed
an increase in the particle size of the lyophilized IAP and
P-IAP, though highly stable. Mannitol, glucose sucrose are
generally used as cryoprotectants in terms of long term
storage, simultaneously preventing aggregation of albumin
based nanocomposite structures.59
Our study focused on increasing the residence time of
contrast in the blood pool by surface modification of IAP
by creating sterically stabilized NPs. The ideal system for
delivery of long circulating contrast agents should have
minimal agent release in vivo which will allow prolonged
imaging studies and repeated scans in CT. Both in vitro
and in vivo studies showed slow release of iohexol from
the surface modified nanoparticle formulation as compared
to bare nanoparticle formulation which, might be due to
existence of a steric hydrophilic barrier on the surface of
the NPs which made digestion of the NPs more difficult.57
It is known that extracellular agents with small molecular
weights such as iohexol have much faster clearance profile
in vivo compared to colloidal carriers such as liposome’s.62
Therefore, as the encapsulated agents are released from
the liposomes, the signal enhancement diminishes in CT 
at a rate that is proportional to that of agent release and 
clearance.
Visualization of organs like heart and kidneys were 
more distinct after injection of PEGylated nanoparti-cle 
formulation as compared to the other formulations. Liver 
enhancement was substantially lower than vascular 
enhancement but remained relatively stable over 180 min; 
this indicates that modification via PEGylation decreases 
first-pass extraction and increase NPs serum half-life. 
Although uptake of NP’s from the blood to the liver 
may occur relatively quickly, hepatic processing and bil-
iary excretion of these particles is relatively slow, result-
ing in prolonged retention within the liver parenchyma 
itself.63 Long circulation of drugs in the body is the key 
to successful drug delivery and drug targeting to the site 
of action.64 In our study PEGylation of iohexol albumin 
NPs was useful in achieving these goals by 
improving the residence time of contrast agent in the 
organs and showed stable enhancement of the intravascular 
space for more than 3 h. similar results were earlier 
reported  [65].
CONCLUSION
Our study showed an efficiently entrapped iohexol in IAP 
and P-IAP nanoformulation, with enhanced residence time 
and produced stable and high opacification of the blood 
pool than the marketed Iopamidol producing much greater 
conspicuity of anatomic features and can be utilized in CT 
imaging and organ visualization. P-IAP showed remark-
able stability, slow release and prolongs retention in differ-
ent organs which made it possible to acquire CT images 
over wide time frame without multiple administration and 
can improve diagnostic accuracy for representation of the 
region of interest. Applications of such nanoparticle 
formulations will open new avenues for the procedures 
which require longitudinal and repeated imaging such as 
image-guided surgical interventions. However, 
improvement in surface modification using functionalized 
PEG and mod-ifying the surface by formation covalent 
bonds might improve the efficacy of IAP. Further to assure 
the safety of such diagnostic tools, a detailed toxicity and 
pharma-cokinetic profile would give better insights to carry 
for-ward to clinics. Although many important goals have 
been achieved in terms of stabilization and longer time of 
con-trast agents in circulation, more investigations are 
needed to study these formulations in diseased animals and 
clini-cal conditions.
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